Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
BGSF BGSF Inc
NEE Nextera Energy Inc
PSB-Y PS Business Parks Inc
ADBE Adobe Inc
APWL Advanced Powerline Technologies Inc
Go

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform, ATH platform and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. Its lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). The Company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019 / ATH-1020 compounds, which are being advanced to address neuropsychiatric indications.

Closing Price
$13.07
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
421,045
0

FRIDAY DEADLINE ALERT - Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating SelectQuote, Inc. (NYSE:SLQT) for Potential Securities Violations and Breach of Fiduciary Duty

8:02 pm ET October 13, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against SelectQuote, Inc. (NYSE:SLQT).

On May 11, 2021, SelectQuote held a conference call in connection with its third quarter 2021 financial results during which it disclosed that its fourth quarter results would be impacted by a "negative cohort and tail adjustment" due to "lower second-term persistency for the 2019 cohort."

On this news, the Company's share price fell $5.50, or 20%, to close at $21.90 per share on May 12, 2021, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made material misrepresentations concerning the following: (1) that SelectQuote's 2019 cohort was underperforming; (2) that, as a result, the Company's financial results would be adversely impacted; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Investors who purchased or otherwise acquired SelectQuote, Inc. ('SelectQuote' or 'the Company') (NYSE:SLQT) securities between February 8, 2021 and May 11, 2021, inclusive (the 'Class Period') are hereby notified that they have until October 15, 2021 to move the Court to serve as lead plaintiff in this action.

If you currently own stock or options in SelectQuote, Inc. and suffered a loss, click here to participate.

If you want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at david@labaton.com.

About the Firm

Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at Labaton.com.

CONTACT:

David J. Schwartz(800) 321-0476david@labaton.com

SOURCE: Labaton Sucharow LLP

View source version on accesswire.com: https://www.accesswire.com/668043/FRIDAY-DEADLINE-ALERT--Nationally-Ranked-Shareholder-Rights-Firm-Labaton-Sucharow-is-Investigating-SelectQuote-Inc-NYSESLQT-for-Potential-Securities-Violations-and-Breach-of-Fiduciary-Duty

comtex tracking

COMTEX_395141988/2457/2021-10-13T20:02:40

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.